EUS fine-needle pancreatic core biopsy can determine eligibility for tumor-agnostic immunotherapy

Background and study aims  The US FDA recently approved a cancer treatment with pembrolizumab based upon the tumor biomarker status of deficient mismatch repair (dMMR) rather than a specific disease-based approach. We sought to determine if endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) c...

Descripción completa

Detalles Bibliográficos
Autores principales: Gleeson, Ferga C., Levy, Michael J., Roden, Anja C., Boardman, Lisa A., Sinicrope, Frank A., McWilliams, Robert R., Zhang, Lizhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: © Georg Thieme Verlag KG 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175678/
https://www.ncbi.nlm.nih.gov/pubmed/30302387
http://dx.doi.org/10.1055/a-0650-4447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175678/
https://www.ncbi.nlm.nih.gov/pubmed/30302387
http://dx.doi.org/10.1055/a-0650-4447

Ejemplares similares